论文部分内容阅读
目的评价放射治疗ⅠE期非结膜原发眼附属器黏膜相关淋巴组织型淋巴瘤的剂量效应和预后。方法回顾性分析2003年11月至2012年3月收治的影像资料完整可测量的33例(42只眼)ⅠE期非结膜原发眼眶黏膜相关淋巴组织型淋巴瘤患者资料。结果当照射剂量分别为18 Gy和27 Gy时,按照WHO标准评价33例患者的缓解率分别为31%和42.9%(P=0.258),按照RECIST标准评价缓解率分别为28.6%和38.1%(P=0.355);33例患者的局部控制率为100%。33例患者的5年、10年生存率分别为96.8%和84.7%,5年、10年无病生存率分别为89.6%和89.6%。接受≥30.6 Gy和27 Gy者的5年、10年生存率分别为100%、80%和95.7%、95.7%(P=0.8578),5年、10年无病生存率分别为83.3%、83.3%和91.1%、91.1%(P=0.6497)。结论非结膜原发眼附属器黏膜相关淋巴组织型淋巴瘤对放疗敏感,27 Gy的照射剂量即可获得较好局部控制和长期生存,确定最佳照射剂量仍需要开展前瞻性大样本的剂量效应研究。
Objective To evaluate the dose-response and prognosis of non-conjunctival primary ocular adnexal mucosa-associated lymphoid tissue lymphoma in stage ⅠE radiotherapy. Methods The data of 33 patients (42 eyes) with stage ⅠE non-conjunctival primary orbital mucosa-associated lymphoid tissue lymphoma were retrospectively analyzed from November 2003 to March 2012. Results The remission rates of 33 patients were 31% and 42.9% (P = 0.258) according to the WHO criteria when the irradiation doses were 18 Gy and 27 Gy, respectively. The response rates of RECIST were 28.6% and 38.1% P = 0.355). The local control rate was 100% in 33 patients. The 5-year and 10-year survival rates of the 33 patients were 96.8% and 84.7% respectively, and the 5-year and 10-year disease-free survival rates were 89.6% and 89.6% respectively. The 5-year and 10-year survival rates of patients who received ≥30.6 Gy and 27 Gy were 100%, 80% and 95.7%, 95.7% (P = 0.8578) respectively. The five-year and 10-year disease-free survival rates were 83.3% and 83.3% % And 91.1%, 91.1% (P = 0.6497). Conclusions The non-conjunctival primary ocular adnexal mucosa-associated lymphoid tissue lymphoma is sensitive to radiotherapy and the local dose and the long-term survival of the 27 Gy irradiation dose can be obtained. the study.